Tools & Assets

Explore the most promising technologies from our research laboratories.

Publications

Explore scientific publications straight from our research laboratories.

Key Opinion Leaders

Look no further for Scientific or Medical Expertise

Startups

Find your next strategic partnership or investment.

Clinical Trials

Explore clinical trials being done at Tulane Medicine.

T-vant: A Novel Adjuvant for Transformative Vaccines

Inducing Immunity at the Source of Infection

Download One-Pager Download Slide Deck

Inducing Immunity at the Source of Infection

T-Vant is a potent adjuvant developed by Tulane scientists. This isolated lipid nanoparticle can stimulate not only the B-Cells and CD4+ T-Cells usually associated with vaccine protection, but also stimulates a potent CD8+ T-cell response. This new technology is suitable for use with any microbe or antigen and has been tested in multiple virus and bacterial challenge models.

Researchers

Why T-vant?

• Robust Multi-Arm Immune Boost

Activates humoral, cellular and mucosal responses, delivering broader, longer-lasting protection.

• Universal Vaccine Compatibility

Works as a simple admix with protein, peptide, inactivated, and other antigens, reducing need for reformulation.

• Dose-Sparing & Single-Shot Potential

Enhances neutralizing titers ≥10-fold and prolongs memory B- and T-cell responses, enabling lower antigen doses or single-dose regimens.

• Clean Safety & Low Reactogenicity

Demonstrates excellent tolerability in mice, rabbits, non-human primates, and the MIMIC human surrogate system.

• Mucosal & Needle-Free Delivery

Retains full adjuvant potency when given intranasally or orally, supporting needle-free mass-vaccination.

Following uptake of T-vant and its antigen payload, T-vant activates immunity across all arms of the immune system; in particular, strong immunity is induced at mucosal tissues, often the site of initial infection.

T-vant provides antigen-agnostic protection against a broad spectrum of respiratory, gastrointestinal, and other infectious diseases.

Publications

A novel outer membrane vesicle adjuvant improves vaccine protection against Bordetella pertussis View
Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization View
An Outer Membrane Vesicle-Adjuvanted Oral Vaccine Protects Against Lethal, Oral Salmonella Infection View
Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses View

Other resources

BIO from the Bayou Podcast: Unveiling the T-vant Adjuvant with Key Opinion Leaders Lisa Morici and James McLachlan View
Title Country Date of Application Serial / ID Number Additional Notes
Bacterial Outer-Membrane Vesicles Derived Adjuvants US 10/09/2020 11,534,486
Bacterial Outer-Membrane Vesicles Derived Adjuvants PCT 04/10/2019 PCT/US2019/026769 Nationalized to "CA, IN, AU. KP. EPO. CN

Explore a Partnership

Flexible collaboration models available — Sponsored Research, Co-Development, Licensing.

For inquiries, contact:
Alexis Ducote, PhD
Business Development Associate
aducote@tulane.edu
337.540.4025

X

Schedule a call

Set up a meeting with one of our team members by using the Calendly integration below.

Is it urgent? Call us:

James Zanewicz (+1 504.919.3800),

Alexis Ducote (+1 337.540.4025),

Carolyn Scofield (+1 504.881.4542).